Puberty blockers are medications that temporarily pause the physical changes of puberty by suppressing the hormones that drive them. They belong to a class of drugs called GnRH agonists (gonadotropin-releasing hormone agonists), and they’ve been used in pediatric medicine since the 1980s, originally to treat children who enter puberty abnormally early. More recently, they’ve become part of gender-affirming care for transgender and gender-diverse adolescents.
How Puberty Blockers Work
Puberty starts when the brain begins releasing GnRH in short, rhythmic pulses. These pulses signal the pituitary gland to produce two hormones that, in turn, tell the ovaries or testes to ramp up estrogen or testosterone production. That rising tide of sex hormones is what triggers breast development, voice deepening, growth spurts, and the other familiar changes of puberty.
Puberty blockers work by flooding the system with a continuous, steady dose of synthetic GnRH instead of the natural pulsed version. This constant exposure causes the pituitary gland’s GnRH receptors to essentially shut down, a process called downregulation. After a brief initial surge, the pituitary stops sending signals to the gonads, and sex hormone levels drop to prepubertal levels. The physical changes of puberty slow or stop as long as the medication continues.
What They’re Prescribed For
The FDA has approved GnRH agonists for central precocious puberty, a condition where children begin developing secondary sex characteristics unusually early, sometimes as young as two or three years old. In these cases, the goal is to hit pause until the child reaches a more typical age for puberty, then allow development to proceed naturally.
The same medications are also prescribed off-label to transgender and gender-diverse adolescents experiencing distress from the physical changes of puberty. In this context, blockers give the young person and their care team more time to explore gender identity before irreversible changes like breast growth or voice deepening progress further. Clinical guidelines from major medical organizations recommend that puberty suppression not begin until a young person has reached at least Tanner stage 2, the earliest visible sign of puberty (such as the beginning of breast budding or testicular enlargement). Starting before any puberty has begun is not recommended, partly because experiencing the initial stages of puberty can be important for a young person’s understanding of their own gender identity.
How They’re Administered
Puberty blockers are typically given as injections on a regular schedule, either monthly or every few months depending on the specific formulation. A small implant placed under the skin of the upper arm is another option; it releases medication steadily and is replaced roughly once a year. The choice between injection and implant often comes down to preference, insurance coverage, and what’s available locally.
Effects on Bone Health
One of the most studied concerns with puberty blockers is their effect on bones. During puberty, rising sex hormones drive a major surge in bone mineral density, and suppressing those hormones interrupts that process. Research consistently shows that long-term puberty suppression leads to measurable decreases in bone density, particularly in the lower spine and hips. In studies tracking adolescents over roughly one to two years of treatment, bone density scores declined relative to peers of the same age.
The good news is that bone density partially recovers once sex hormones are introduced, either by stopping blockers and allowing natural puberty to resume, or by starting hormone therapy. However, recovery is not always complete, especially at the spine. Because of this, guidelines recommend bone density scans at baseline and every one to two years during treatment, continuing until peak bone mass is reached (typically by the mid-to-late twenties). Adequate calcium intake of at least 1,000 milligrams per day, vitamin D supplementation, and regular weight-bearing exercise like running or jumping are all advised during treatment.
Fertility Considerations
Puberty blockers pause the maturation of eggs and sperm. While a young person is on the medication, their reproductive cells are not developing toward the maturity needed for reproduction. If blockers are stopped and natural puberty resumes, this maturation process is expected to pick back up. The concern becomes more significant if a young person moves directly from puberty blockers to cross-sex hormone therapy without ever going through their endogenous puberty, because they may never produce mature gametes.
For prepubertal individuals who haven’t yet developed mature eggs or sperm, fertility preservation options are limited and still considered experimental. Major medical organizations recommend that clinicians discuss fertility and preservation options with the adolescent and their family before starting treatment, so families can make informed decisions about the tradeoffs involved.
Reversibility
Puberty blockers are generally described as reversible. Stopping the medication leads to a prompt reactivation of the hormonal signaling chain between the brain, pituitary gland, and gonads. Puberty then resumes along its original trajectory. This is one of the key distinctions between blockers and hormone therapy: blockers delay, while hormones actively redirect development.
That said, “reversible” doesn’t mean “without consequence.” The years spent on blockers are years without the bone density gains, growth, and reproductive cell maturation that would normally occur during that window. Whether those effects are fully recoverable over time depends on the individual and how long treatment lasted.
Mental Health Outcomes
A large study from the University of Washington found that transgender youth who received puberty blockers or gender-affirming hormones had 60% lower odds of depression and 73% lower odds of self-harm or suicidal thoughts compared to those who did not receive these treatments. The study did not find a similar correlation with anxiety, suggesting the mental health benefits may be specific to mood and suicidality rather than broadly reducing all forms of psychological distress.
These findings are significant given the elevated rates of depression and suicidality among transgender youth as a population. However, mental health outcomes in this area remain an active and sometimes contested area of study, and individual responses to treatment vary.
Who Guides These Decisions
The most widely referenced clinical framework is the Standards of Care published by the World Professional Association for Transgender Health (WPATH), now in its eighth version. SOC-8 recommends GnRH agonists as the preferred method of puberty suppression when indicated, with progestins as an alternative when GnRH agonists are unavailable or too expensive. The guidelines emphasize an ongoing relationship between the young person, their family, and a multidisciplinary care team throughout the duration of treatment.
Eligibility is not simply a matter of age. The guidelines specify that the adolescent must have reached at least Tanner stage 2, that gender diversity must be well-documented and persistent, and that any coexisting mental health concerns are being addressed. The process is designed to be collaborative, with the adolescent actively involved in decisions about their own care as treatment progresses.